Trial Profile
A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Adenocarcinoma; Liver metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms ALTER0303
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 01 Apr 2023 Results of post hoc analysis (n=437) assessing the effects and prognosis in non-small cell lung cancer patients with liver metastasis patients treated with anlotinib, published in the Journal of Cancer Research and Clinical Oncology.
- 14 Sep 2021 Results of this post-hoc analysis assessing the effect and safety of Anlotinib as a third line or further therapy in non-small cell lung cancer patients with liver metastasis presented at the 2021 World Conference on Lung Cancer
- 20 May 2020 Results assessing cost-effectiveness of anlotinib as the third-line and further therapy from the Chinese payer perspective using data from this trial, presented at the 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.